Long-Term Evaluation of BIIB067 (Tofersen)

Completed · Phase 3

Conditions studied: ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation

In brief

The primary objective of the study is to evaluate the long-term safety and tolerability of BIIB067 (tofersen) in participants with amyotrophic lateral sclerosis (ALS) and confirmed superoxide dismutase 1 (SOD1) mutation. The secondary objectives are to evaluate the pharmacokinetic (PK), pharmacodynamic (PD), biomarker effects, and efficacy of BIIB067 administered to participants with ALS and a confirmed SOD1 mutation.

Key facts

Study ID
NCT03070119
Run by
Biogen
People needed
139
Starts
2017-03-08
Expected to finish
2024-08-12
Last updated by the study team
2025-08-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.